Last Updated 00:00:00
longbridge loading
Company Encyclopedia
name
Bloomage Biotech
688363.SH
Bloomage BioTechnology Corporation Limited researchers, develops, produces, and sells bioactive materials. It offers pharmaceutical grade sodium hyaluronate which can be used as an API or excipient for drugs and medical devices in ophthalmic preparations, intra-articular injections, anti-adhesive preparations, and topical preparations for wound healing and soft tissue filler under the Hyature name; and cosmetic grade sodium hyaluronate solutions for cosmetic products, including moisturizing, repairing, delay skin aging, and brightening under the Hybloom, miniHA, microHA, Hyacross, Hyacolor, and cationHA. The company also provides food-grade sodium hyaluronate for use in food/healthy food/dietary supplements under the HAPLEX name, as well as food-grade gamma aminobutyric acid under the Gabarelax name; hyaluronic acid for oral care under the Biomoist name; and animal care products under the HYAPET names. Bloomage BioTechnology Corporation Limited was founded in 2000 and is based in Jinan, China.
229.44 B
688363.SHMarket value -Rank by Market Cap -/-

Financial Score

19/05/2026 Update
C
Personal Care ProductsIndustry
Industry Ranking17/28
Industry medianC
Industry averageB
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE3.63%C
    • Profit Margin6.45%B
    • Gross Margin67.84%A
  • Growth ScoreD
    • Revenue YoY-22.36%E
    • Net Profit YoY677.04%A
    • Total Assets YoY2.49%C
    • Net Assets YoY2.90%C
  • Cash ScoreC
    • Cash Flow Margin306.64%A
    • OCF YoY-22.36%E
  • Operating ScoreC
    • Turnover0.46C
  • Debt ScoreA
    • Gearing Ratio18.18%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News

    Hesai 4Q25 First Take: Results again showed high shipment growth driven by price compression. The company protected margins via solid cost control and issued upbeat 2026 shipment guidance. I. 4Q25 results: volumes up, prices down, profitability remained resilient 1) Revenue: RMB 1.0 bn, +39% YoY. This was at the low end of prior guidance (RMB 1.0–1.2 bn) and slightly below the RMB 1.08 bn consensus. Shipments: 631k units, +184% YoY, beating guidance (600k) and the 619k consensus. Growth was driven by robot LiDAR (80k units, above the 50k expected) and the continued ramp of ADAS LiDAR (550k units). ASP: RMB 1,557, down 51% YoY and 13% QoQ, well below the RMB 1,718 the market expected. This directly explains the revenue miss vs. consensus. Dolphin Research sees three main drivers of the faster ASP decline: a) Product mix shift: the low-priced 'thousand-yuan' ATX rose from 70% in Q3 to ~80% in Q4. It accelerated the replacement of the older AT128, which sells for multiples of that price. b) Proactive discounts: to defend share, the co. offered ATX discounts to key customers in Q4. This weighed on blended pricing. c) Robot mix: within robot shipments, the lower-priced JT series likely accounted for a higher share. This further dragged ASP. 2) Despite a sharp ASP decline, HSAI showed resilient profitability. Margin held up better than feared. GPM: 41.0%. This was above the 39.7% consensus and the company's 40% guide. We attribute this to scale benefits from higher volumes and ongoing cost downs from in-house ASICs, supply-chain optimization, and factory automation. These gains offset pricing pressure. 3) Net profit at the top end: GAAP net profit was RMB 150 mn, at the high end of guidance (RMB 70–170 mn). This was boosted by interest income and other gains (~RMB 120 mn). In Q4, HSAI received ~$6.4 mn (~RMB 45 mn) in IP arbitration compensation from Ouster. Excluding these items, core OP was ~RMB 40 mn (GP minus core Opex), slightly below the RMB 60 mn expected, mainly due to higher R&D and S&M QoQ. Overall, expense control remained disciplined. II. 2026 guidance: shipment targets raised materially Mgmt is upbeat on 2026, guiding well above prior market expectations. The tone signals confidence in volume growth. 2026 shipment guide: 3.0–3.5 mn units (+185%–216% YoY). This is a major step-up from the prior 2.0–3.0 mn range and is well above the 2.66 mn street. To support this, the co. plans to double annual capacity to 4.0 mn units from 2.0 mn in 2025. Q1 pricing likely stable to up: 2026 Q1 net revenue guidance is RMB 650–700 mn (+24%–33% YoY). Given Q1 is typically a seasonal trough for autos (about 12% of annual shipments historically), the midpoint of the full-year guide implies ~393k units in Q1. Back-solving implies a blended Q1 ASP of ~RMB 1,675, slightly above 4Q25's RMB 1,557. We think this reflects slower passenger-car LiDAR shipments in Q1 and a higher mix of higher-priced robot/industrial LiDAR. $Hesai(HSAI.US) $HESAI-W(02525.HK)